Home » Newsletters » BioWorld Asia

BioWorld Asia

Sep. 13, 2000

View Archived Issues

PowderJect To Pay US$79.2M For Celltech's Vaccine Arm

Cureon To Develop Therapeutic Applications Of LNA Platform

Cell Therapy More Promising After Stem Cell Breakthrough

Peptor Diabetes Drug Looks Promising At Phase II Interim

European Parliament Condemns British Decision To Allow Cloning

Antisoma Harnesses Cyanide, Antibodies For Cancer Therapy

Medarex To Create Antibodies For OGS Proteomics Targets

IsoTis Gearing Up For Trials, October Stock Market Float

ExonHit Raises US$12M, Prepares For IPO In 2001

Biotie Targets Inflammation Protein With Dual Activity

Amrad Advances Clinical Slate, Including HBV, Pain Therapies

Other News To Note

Bionomics Seeking Partners For Cancer, Epilepsy Genes

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...